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Abstract Zinc exists in biological systems as bound and
histochemically reactive free Zn2+ in the nanomolar range.
Zinc is required as either structural or catalytic component
for a large number of enzymes. It also modulates current
passage through many ion channels. Here, we reinvestigated
the effects of extracellular and intracellular Zn2+ on the L-
type Ca2+ current (ICaL) and its modulation by β-adrenergic
stimulation in rat ventricular cardiomyocytes. In the absence
of Ca2+ ions, Zn2+ could permeate through the L-type chan-
nel at much lower concentrations and at a more positive
voltage range, but with a lower permeability than Ca2+. In
the presence of Ca2+, extracellular Zn2+ demonstrated strong
bimodal inhibitory effects on the ICaL, with half-inhibition
occurring around 30 nM, i.e., in the range of concentrations
found in the plasma. Intracellular Zn2+ also significantly
inhibited the ICaL with a half-inhibitory effect at 12.7 nM.
Moreover, β-adrenergic stimulation was markedly reduced
by intracellular Zn2+ at even lower concentrations (<1 nM)
as a consequence of Zn2+-induced inhibition of the adenylyl
cyclase. All these effects appeared independent of redox
variations and were not affected by dithiothreitol. Thus, both
basal intracellular and extracellular Zn2+ modulate trans-
membrane Ca2+ movements and their regulation by β-
adrenergic stimulation. Considering that, in many patholog-
ical situations, including diabetes, the extracellular Zn2+
concentration is reduced and the intracellular one is in-
creased, our results help to explain both Ca2+ overload and
marked reduction in the β-adrenergic stimulation in these
diseases.
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Introduction
Zinc, the most abundant transition metal in the body, second
to iron, is an important nutrient and an essential catalytic or
structural component in thousands of enzymes involved in
cellular signaling pathways and transcription factors. In
eukaryotic cells, total Zn2+ concentration can be up to
200 μM (not very different from the Ca2+ one), with 30 %
localized in the nucleus, 50 % localized in the cytosol and
organelles, and the remainder associated with proteins [54].
In cardiomyocytes, the intracellular free Zn2+ concentration,
[Zn2+]i, has been measured to be <1 nM in physiological
conditions [28, 53], similar to those reported in HT-29 cells
[34], i.e., about 100-fold less than [Ca2+]i. At various con-
centrations, Zn2+ increases the cell’s antioxidant capacity or
leads to the release of toxic reactive oxygen species (ROS)
[37]. [Zn2+]i is increased by 70 % in diabetes [7] and over
200 % in aldosteronism [28]. Moreover, oxidants caused
about a 30-fold increase in [Zn2+]i but only doubled [Ca
2+]i
in cardiomyocytes [53]. Zinc homeostasis in mammalian
cells results from a coordinated regulation by different pro-
teins involved in the uptake, excretion, and intracellular
storage/trafficking of Zn2+ [41]. Zn2+ influx is facilitated
by ZIP (solute-linked carrier, SLC39) proteins and may
occur through different channels including the L-type Ca2+
channels in heart cells [6] as well as L-type and N-type Ca2+
channels in neurons [32] and was reported earlier in insect
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muscle [17]. Intracellular Zn2+ is thought to be in equilibri-
um with many soluble cytosolic Zn2+ binding proteins, such
as metallothionein/thionein, and large variations in [Zn2+]i
are mediated by Ca2+ along each cardiac cycle [51]. It was
thus suggested that the Ca2+-dependent Zn2+ release con-
tributes to controlling the redox status during each cardiac
cycle. Fluctuations of intracellular Zn2+ participate in im-
portant cellular functions, as have been recently demonstrat-
ed in TamR cells from MCF-7 breast cancer cells where a
regulated release of Zn2+ from the endoplasmic reticulum,
through the action of protein kinase CK2 on zinc channel
ZIP7, is involved in proliferation and cell migration [46].
Besides, a dyshomeostasis of extracellular and intracellular
Ca2+ and Zn2+ contributes to an imbalance of pro-oxidants
and antioxidants in favor of pro-oxidants such as that occur-
ring during various diseases including diabetes or aldoste-
ronism [27, 28].
Free Zn2+ modulates many membrane receptors, trans-
porters, and channels. It inhibits the activity of types I, V,
and VI adenylyl cyclases (AC) as well as the hormone and
forskolin (FSK) stimulation of cAMP synthesis in N18TG2
cells [33] and, by preventing GTP binding to the GTPase,
reduces Gαs function [19]. Zn2+ inhibits several isoforms of
purified recombinant PDE, including the cAMP-dependent
PDE-3 and PDE-4A [56], as well as Ser/Thr or Tyr phos-
phoprotein phosphatases [23], although low Zn2+ is needed
for the phosphatase activities. Picomolar Zn2+ concentra-
tions strongly inhibit receptor protein tyrosine phosphatase
β activity (Ki, ∼20 pM), indicating a physiological rather
than physiopathological or toxicological role, strongly sug-
gesting a modulatory activity of signal transduction process-
es by Zn2+ [57]. Also, in the presence of Ca2+ and
calmodulin, increasing concentrations (in micromolars) of
Zn2+ caused a progressive inhibition of substrate phosphor-
ylation by CaMKII such as to produce a concentration-
dependent inhibition of phospholamban phosphorylation
[8]. Moreover, Zn2+ induces aggregates of pure tubulin,
implying that the activation of G proteins by tubulin dimers
[22] would be prevented. Zn2+ also inhibits protein kinase C
(PKC) [9]. However, the relationship between Zn2+ and
PKC activity is far more complex since it has been shown
that Zn2+ is a vital factor allowing, through dynamic
changes in response to specific signals, to turn on or off
PKC activity [35].
Both T-type Ca2+ current and L-type Ca2+ current (ICaL) are
inhibited by external Zn2+ [49, 52], and intracellular Zn2+
loading also reduces ICaL [52]. Surface charge effects could
be invoked to explain some of the Zn2+ actions. However, as
for other divalent metal cations, most of the effects of Zn2+
could be well explained by changes in the gating of ion
channels. For example, it has been shown that blocking of
Na+ and K+ channels by Zn2+ demonstrates a high potency
and quite different effects on the activation and deactivation
gating rather than a surface screening effect, suggesting spe-
cific binding sites within the channel [20, 21, 59]. Further-
more, squid K+ channels are far more sensitive to Zn2+ than
Na+ channels, but the interactions of Zn2+ with gating charges
appear similar in both cases [20]. Of note, the action of
external Zn2+ on K+ channels is inhibited by an amino group
reagent, but not by sulfhydryl reagents, and is mimicked by
histidine-modifying reagents [43]. Recently, it was reported
that, during sublethal ischemia, the early rise in neuronal Zn2+,
preceding the rise in intracellular Ca2+, is responsible for the
hyperpolarizing shift in the voltage dependency of the delayed
rectifier Kv2.1 channels [4].
Ca2+ channels are modulated by many mechanisms in-
cluding phosphorylation, nitrosylation, and specific thiol
oxidation [25, 55]. Intracellular Zn2+ distribution is linked
to redox metabolism, but Zn2+ itself is not redox-active and
Zn2+ proteins are redox-inert. However, zinc coordination
environments with cysteine ligands have the remarkable
property that the sulfur ligands can be oxidized and then
reduced with concomitant release and binding of Zn2+ [36,
37]. Moreover, Zn2+ elevates ROS in living cells by inhibit-
ing mitochondria [15] and activating NADPH oxidase [38].
Consequently, it can be foreseen that Zn2+ may alter L-type
Ca2+ channel properties by altering the cellular redox status.
Furthermore, redox also modulates β-adrenergically stimu-
lated ICaL [42]. Although there is some evidence that, in
cardiomyocytes, Zn2+ blocks ICaL [52] and that it can per-
meate through the L-type Ca2+ channel, though at a high
concentration [6], there is still a need to better understand
these processes in heart cells. In the present work, we have
reinvestigated the blocking effects and the permeation prop-
erties of Zn2+ ions through the L-type Ca2+ channel and the
consequences of variations in [Zn2+]i on the characteristics
of ICaL. It is further demonstrated that intracellular Zn
2+
directly inhibits β-adrenergic stimulation, independently of
altering the redox status.
Methods
Experiments were performed using male adult Wistar (180–
200 g) rats according to the procedures approved by the
National Centre for Laboratory Animals (CENPALAB).
Hearts were quickly removed and placed in cold Ca2+-free
Tyrode solution (K+-Tyrode) composed of the following (in
millimolars): 117 NaCl, 4 KCl, 1.5 KH2PO4, 4.4 NaHCO3,
1.7 MgCl2, 10 HEPES, and 10 glucose, pH 7.4. After
careful dissection, hearts were mounted on a Langendorff
column and washed for ∼2 min with Tyrode solution con-
taining EGTA (0.23 mM) at 35 °C. Hearts were then per-
fused with K+-Tyrode containing Ca2+ (∼100 μM) and
collagenase (Worthington CLS2, USA) and recirculated for
7–10 min. After this period, hearts were cut into small
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pieces and gently agitated for 2–3 min in fresh enzyme
solution but supplemented with Ca2+ (300 μM) and bovine
serum albumin (BSA, 1 mg/mL). The solution was then
filtered through a nylon mesh (250 μm) and centrifuged at
200 rpm for 2 min. The resulting pellet was washed with a
K+-Tyrode solution without enzymes containing 0.5 mM
Ca2+ and BSA. The solution was left for decantation for
5–10 min and the pellet was again washed with a K+-Tyrode
solution containing 1 mM Ca2+ and BSA. Myocytes thus
obtained were kept at room temperature (21±2 °C) and used
for experiments for 6 h.
Whole-cell currents were recorded at room temperature
according to Hamill et al. [24] using an RK-300 patch clamp
amplifier (Biologic, France), an AD/DA converter (Labmas-
ter DMATL-1-125, Mentor, OH, USA), and the ACQUIS1
software (CNRS License, France). The sodium current was
blocked with tetrodotoxin (50 μM; TTX; Alomone, Israel)
and potassium currents were blocked by substituting all
potassium by cesium in “extracellular” and “intracellular”
solutions. The extracellular solution contained (in millimo-
lars): 117 NaCl, 20 CsCl, 10 HEPES, 2 CaCl2, 1.8 MgCl2,
and 10 glucose, pH 7.4. The standard pipette (intracellular)
solution contained (in millimolars): 130 CsCl, 0.4 Na2GTP,
5 Na2ATP, Na2-creatine phosphate, 11 EGTA, 4.7 CaCl2
(free Ca2+, 108 nM), and 10 HEPES, with pH adjusted to
7.2 with CsOH. In the experiments, cells were first left to lie
in Petri dishes filled with K+-Tyrode solution with 1 mM
Ca2+. Cells attached to the micropipette could be positioned
on the extremity of each of six microcapillaries (i.d.
250 μm) through which the different extracellular Cs+-con-
taining solutions were perfused by gravity (∼15 μL/min),
allowing rapid changes (1 s) to the extracellular medium.
FSK and nifedipine were prepared as 10 mM stock solutions
in ethanol. Except TTX, all chemicals were purchased from
Sigma Chemical Co. (USA).
In some experiments, cells were intracellularly perfused
with Zn2+-containing pipette solutions at concentrations of
0.1, 0.3, 1, 3, 10, or 30 nM. In each case, CaCl2, ZnCl2, and
MgCl2 concentrations of the pipette (intracellular) solution
were adjusted with the Maxchelator software so as to keep
free Mg2+ and Ca2+ at ∼45 μM and ∼120 nM, respectively,
together with the desired free Zn2+ concentration. It must be
noted here that, at very low (0.1 and 0.3 nM) and high (30 nM)
Zn2+ concentrations, calculations must be considered as ap-
proximate intracellular concentrations. After breaking the
patch, cells were let to stabilize for at least 5 min before
beginning the recordings to ensure adequate intracellular per-
fusion with the desired Zn2+ concentration. In some experi-
ments, EDTA was used instead of EGTA in the zero Zn2+
intracellular solution. Since both the density and kinetics of
ICaL in the EDTA-containing solution were similar to those
obtained with the standard EGTA solution, the results for zero
Zn2+ intracellular solutions were pooled together.
Pipette resistance was 1.0–1.2 MΩ. Membrane capacitance
(Cm) and series resistance (Rs) were calculated on voltage-
clamped cardiomyocytes according to the equations:
Cm ¼ tCI0=V 1 Iss=I0ð Þð Þ and Rs ¼ tC=Cm
where τC is the membrane time constant, I0 is the peak capac-
itive current, Iss is the current at the end of the 10-ms pulse, and
V is the amplitude of the voltage step (2 mV; hyperpolarizing).
The current data of each cell was normalized to cell capacitance
(current density in picoamperes per picofarad). AverageCm and
uncompensated Rs were 172±10 pF and 4.1±0.3 MΩ, respec-
tively (N072). Rs could be electronically compensated up to
50%without ringing andwas continually monitored during the
experiment. Liquid junction potential was compensated before
establishing the gigaseal. No leak or capacitance subtractions
were performed in the recordings.
ICaL was routinely monitored at 0 mV using 200-ms
pulses from a holding potential (HP) of −80 mV and mea-
sured as the difference between peak inward current and the
current level at the end of the 200-ms pulse. Zn2+ currents
were measured as the difference between peak current and
the current recorded in the presence of Ca2+ at the end of the
200-ms pulse. Current-to-voltage (I–V) and availability
curves were constructed using standard voltage clamp pro-
tocols. Activation curves for ICaL were obtained by calcu-
lating the Ca2+ chord conductance for each membrane
potential and normalizing to maximal conductance [1]. Po-
tential for half-activation and availability and the
corresponding slope factors were obtained after fitting the
experimental data to Boltzmann functions. The inactivation
time course of ICaL was fitted to a double exponential using
the fitting procedures of the ACQUIS1 software. Currents
were filtered at 3 kHz and digitized at 50-μs intervals.
Results were analyzed using the statistical routines of Gnu-
meric Spreadsheet (Gnome Project, version 1.10.17) and are
expressed as means and standard errors of means. Statistical
significance was evaluated by means of paired or unpaired
Student’s t test according to the experimental situation. Differ-
ences were considered statistically significant for p<0.05.
Results
Effects of external Zn2+ on the L-type current
When extracellular Ca2+ is lowered below micromolar lev-
els, voltage-gated L-type Ca2+ channels become highly per-
meable to other cations. After substituting 2 mM Ca2+ by
Zn2+, an inward current carried by Zn2+ ions, IZn, could be
elicited that exhibited, however, slower kinetics than ICaL
(Fig. 1a). Time-to-peak was increased about fourfold, while
IZn maximal density, which occurred at about +20 mV, was
markedly reduced compared to ICaL. IZn inactivation was
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monoexponential with time constants larger than 75 ms at
potentials over +50 mV (Fig. 1c; Table 1). Of note, Zn2+ and
Ca2+ current deactivations were not significantly different
from each other (not shown). The current–voltage relation-
ship demonstrated a significant rightward shift with a half-
activation, V0.5, of +7.5 and −14.0 mV in Zn2+ and Ca2+,
respectively (Fig. 1d; Table 1). Voltage-dependent inactiva-
tion of IZn was incomplete, with availability remaining over
65 %. Half-availability was also shifted by the charge carrier
Zn2+, although to a lower extent than activation. Remarkably,
despite IZn having a relatively low peak amplitude, the affinity
of the L-type channel for Zn2+ appeared much higher than the
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one for Ca2+. IZn peaked at 1.19±0.07 pA/pF with 20 mM
extracellular concentration (measured at +30 mV), instead of
22.6±1.2 pA/pF with 20 mM Ca2+ (peak current measured at
+40 mV to take into account screening effect), while the
concentration–current density curves suggest a Kd of
0.043 mM for Zn2+ vs. 4.8 mM for Ca2+ (Fig. 1e). Nifedipine
strongly inhibited IZn, although with a less potency than ICaL
with an IC50 of ∼3 vs. 0.3 μM, respectively. The ability of low
pHo to reduce ICaL in cardiomyocytes is well established [58].
However, as was previously reported in cortical neurons [32],
acidic pH (6.4) induced an increase in IZn, an effect that, here in
cardiomyocytes, occurred independently of voltage, with IZn
reversal potential being unaffected (Fig. 1f). Neither IZn kinet-
ics nor IZn activation and availability curves were modified.
Like other divalent cations, Zn2+ competes with Ca2+ to
carry the L-type current. Adding 0.3 mM Zn2+ to the control
external solution containing 2 mM Ca2+ induced a signifi-
cant (∼50 %) reduction in peak inward current while affect-
ing current kinetics or voltage dependency (Fig. 2a, b;
Table 1). On the other hand, adding 0.3 mM Ca2+ to the
external solution containing 2 mM Zn2+ had very little effect
on the current characteristics. Current kinetics and current–
voltage curves obtained in a solution that contained Ca2+
and Zn2+, both at 2 mM, had intermediate characteristics.
We explored in more detail ICaL inhibition by extracellu-
lar Zn2+ using extracellular EDTA (1 mM) to buffer Zn2+
concentration at a fixed extracellular Ca2+ concentration
(2 mM) and studying a wider range of Zn2+ concentration.
Surprisingly, ICaL was already significantly reduced by
nanomolar concentrations of external Zn2+, such that the
concentration-dependent inhibition of ICaL by external Zn
2+
was bimodal (Fig. 2c). Considering that Zn2+ ion enters the
cell aside from Ca2+, it is difficult to calculate inhibition
constants. However, a first peak of inhibition occurred at
10–100 μM Zn2+, suggesting a high-affinity inhibitory site
with half-maximal inhibition at an extracellular Zn2+ concen-
tration around 30 nM. Both fast and slow inactivation time
constants of ICaL were significantly increased at extracellular
Zn2+ concentration of 10 μM or higher (Fig. 2d).
Effects of internal Zn2+ on the L-type Ca2+ current
It has been reported that an increase in intracellular Zn2+ using
the Zn2+ ionophore, pyrithione, reduces the ICaL [52]. Patch
pipette solutions containing calculated free Zn2+ of 0.1 to
30 nM, keeping free Ca2+ and Mg2+ at the required concen-
trations, significantly reduced ICaL at all voltages (Fig. 3a, b).
Concurrently, ICaL time-to-peak increased with increasing in-
tracellular Zn2+ (Fig. 3c). As well, the fast and slow inactiva-
tion time constants of ICaL (τfast and τslow, respectively) were
also increased with increasing intracellular Zn2+, although the
latter was only significantly increased at 10 and 30 nM con-
centrations (Fig. 3c). The increase in time constants occurred
probably as a consequence of the reduced Ca2+-dependent
inactivation process. Furthermore, the availability curve was
rightward shifted, by up to 7.1±0.9 mV with 10 and 30 nM
intracellular Zn2+ (not shown). The Zn2+-induced inhibitory
effect occurred with an apparent IC50 of 12.7 nM (Fig. 3d).
Internal Zn2+ reduced β-adrenergic stimulation
of the L-type current
While performing the above experiments, a quite intriguing
observation was that β-adrenergic stimulation was markedly
attenuated in the presence of increased intracellular free Zn2+.
These observations led us to analyze the effects of 1 μM
isoproterenol (ISO) under a variety of experimental conditions.
Fig. 1 Ca2+ and Zn2+ currents through the Cav 1.2 channel. a Represen-
tative Ca2+ currents recorded from a cardiomyocyte in a 2-mMCa2+–0-mM
Zn2+ extracellular solution and after switching to a 0-mMCa2+ extracellular
solution with 2 mM Zn2+. HP was set at −80 mVand 200-ms pulses were
applied to membrane potentials from −40 to +70 mV (10-mV increases).
Note the slower activation and inactivation kinetics of Zn2+ currents. b
Current–voltage relationships with Ca2+ or Zn2+ as charge carrier. Points
represent means (±SEM) of 20 cardiomyocytes. cMeans (±SEM;N020) of
fast (τfast) and slow (τslow) inactivation time constants of Ca
2+ current (ICaL)
showing the typical “U-shaped” voltage dependency. The inactivation time
course of Zn2+ current (IZn) could be fitted to only one exponential. d
Availability and activation curves obtained in 2 mM Ca2+/Zn2+-free and
2 mM Zn2+/Ca2+-free extracellular solutions in 20 cardiomyocytes (means
±SEM). Activation curves were obtained by estimating the chord conduc-
tance and assuming reversal potentials of +52 and +47 mV for Ca2+ and
Zn2+ currents, respectively. Conductance values obtained for each mem-
brane potential were normalized to maximal conductance. V0.5 and s for
activation (obtained from the fit to Boltzmann functions) were −14.03 and
6.8 mV for Ca2+ and 7.5 and 8.76 mV for Zn2+, respectively. Availability
curves were obtained from the fitting to Boltzmann functions between −70
and 0mV for ICaL and between −70 and +20mV for IZn. Potentials for half-
inactivation (V0.5) and slope factors (s) were −31.5 and 6.4 mV for ICaL and
−20.2 and 10.6 mV for IZn. The inset shows the 200-ms paired pulse
voltage clamp protocol used to obtain the availability curve. Note that,
while V0.5 for activation (and peak inward current) of IZn is shifted right-
ward by ∼20 mV, V0.5 for availability of IZn was shifted rightward by only
∼10 mV. However, the IZn current shows a remarkably weak voltage-
dependent inactivation with a minimum in availability of 0.66±0.03 at
+20 mV. e IZn (in Ca
2+-free extracellular solution) and ICaL (in Zn
2+-free
extracellular solution), current densities as a function of extracellular Ca2+
or Zn2+ concentration. Values represent the means (±SEM) of maximal
Zn2+ currents: at 0mV for [Zn2+]out 0.03mM (N07) and 0.05mM (N010);
at +20mV for [Zn2+]out 2 mM (N025); and at +30mV for [Zn
2+]out 20mM
(N06). Maximal Ca2+ currents were measured at 0 mV for 1 and 2 mM
[Ca2+]out and at +20 and +40 mV for 10 and 20 mM [Ca
2+]out, respectively.
Experimental points were fitted to a Hill function with Imax, concentrations
for half-maximal currents, I50, and Hill numbers of 1.2 pA/pF, 0.043 mM,
and 2.3 for IZn and 31 pA/pF, 4.8 mM, and 0.95 for ICaL. f Current–voltage
relationships for IZn in 0 mM Ca
2+ extracellular solution (means±SEM) at
physiological and acid pH (N07). The inset shows ICaL recorded in 2 mM
Ca2+–0 mM Zn2+ extracellular solution in a cardiomyocyte in control
condition and after reducing the extracellular pH to 6.4 (left) and IZn
recorded from the same cardiomyocyte in 2 mM Zn2+–0 mM Ca2+ extra-
cellular solution in the same conditions (right). Note that extracellular
acidosis slightly decreased ICaL but increased IZn

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The application of ISO was nearly without effect on the
current carried by Zn2+ (Fig. 4a; Table 2). However, the β-
adrenergically stimulated IZn was markedly larger when ISO
had been initially applied in the presence of Ca2+, before
switching to the 2-mM Zn2+-containing solution (Fig. 4b).
The ISO-stimulated current–voltage relationship established
after 5 min in the presence of Zn2+ exhibited a peak at
+10 mV and had a 15-mV less positive reversal potential
compared to the IZn–voltage relationships established in control
and ISO-stimulated conditions (Fig. 4c). The availability curve
also demonstrated intermediate characteristics between the
Ca2+ and Zn2+ availability curves with a V0.5 inactivation of
−19.4 mVand a much larger voltage-dependent current recov-
ery from inactivation but unaffected half-availability (−19.4
and −19.2 mV in control and ISO, respectively; Fig. 4d). Sim-
ilarly, IZn kinetics estimated at +20 mV were markedly slowed
compared to ICaL, with similar time-to-peak, although inactiva-
tion was slightly faster than the one of IZn recorded in the
control or the ISO-added Zn2+-containing solution (Table 2).
Very similar effects on IZn were obtained when applying FSK
(3 μM) instead of ISO, while the addition of 30 μM cAMP to
the pipette solution led to large increases in IZn (Table 2).
Considering that cAMP levels might be reduced by elevat-
ed intracellular Zn2+ (see Introduction) and that oxidation of
thiols on the protein could positively [11] or negatively [42]
alter PKA activity, we checked the effect of ISO on the Zn2+
current in the presence of an oxidant, H2O2, and a sulfhydryl-
reducing agent dithiothreitol, DTT. Here, we show that acute
exposure to H2O2 did not significantly modify ICaL or IZn,
although IZn was slightly reduced. In the presence of H2O2,
ISO application on IZn was still without effect and demon-
strated much reduced effects on ICaL or on IZn elicited after
ISO had been applied in the presence of Ca2+. DTT did not
alter the effects of ISO on IZn whenever ISO was initially
applied in the presence of Zn2+ or Ca2+ (Table 2).
In a second series of experiments, ISO stimulation of ICaL
was analyzed in the presence of intracellular Zn2+ concen-
trations varying from 0.1 to 30 nM and shown above to
partially reduce peak ICaL (see Fig. 3b). Thus, a submaximal
ISO concentration (1 μM) known to increase ICaL over 60 %
in control experimental series induced only a 15 and 5 %
increase in ICaL in the presence of 10 and 30 nM intracellular
Zn2+, respectively (Fig. 5). This effect was unaffected by the
presence of DTT. With 1 nM Zn2+ in the pipette solution,
the ISO effect was already attenuated by more than 50 %.
The half-inhibitory effect of Zn2+ on β-adrenergic stimula-
tion of ICaL occurred at 0.81 nM. However, 30 μM cAMP
added to the pipette solution was equally potent to increase
ICaL independently of the presence or absence of 30 nM
intracellular Zn2+.
Discussion
In this work on cardiomyocytes, we report that Zn2+ can
carry charges through the nifedipine-sensitive L-type Ca2+
channels with a greater affinity than Ca2+. Also, Zn2+ exter-
nally (0.1 to 100 μM) as well as internally (0.3 to 30 nM)
modulates ICaL. Importantly, intracellular Zn
2+ at even lower
concentrations (<1 nM) inhibits β-adrenergic stimulation,
probably by altering the AC activity since the direct activa-
tion of the cAMP-dependent protein kinase A still increases
ICaL in the presence of intracellular Zn
2+. The latter effect
may account, in part, for the reduced β-adrenergic stimula-
tion generally reported in diseased hearts that show an
increased basal Zn2+ level; it also appears independent of
the Zn2+ effect on redox.
Cationic currents, particularly the ICaL, can be modulated
by many mechanisms including phosphorylation, thiol oxi-
dation, and nitrosylation, besides a direct metal ion effect in
Table 1 Effects of extracellular Zn2+ on kinetic properties of the L-type current
Extracellular divalent
(mM)
Time-to-peak
(ms)
τfast (ms) τslow (ms) Inactivation Activation Number
V0.5 (mV) s (mV) V0.5 (mV) s (mV)
2 Ca2+ (0 Zn2+) 4.1±0.1 5.4±0.5 58.4±6.6 −31.5±1.6 6.4±0.4 −14.0±1.2 6.8±0.6 20
2 Ca2++0.00003 Zn2+ 4.2±0.2 6.6±1.8 56.7±3.6 −32.8±2.6 6.6±0.7 −13.8±1.8 6.7±0.7 5
2 Ca2++0.003 Zn2+ 4.4±0.3 7.4±2.1 67.1±4.2 −37.2±2.5* 7.2±0.6 −14.3±2.0 6.9±0.8 5
2 Ca2++0.01 Zn2+ 5.2±0.5 7.8±2.2 76.5±4.7* −36.1±2.2* 7.9±0.6* −14.2±2.3 7.1±0.5 6
2 Ca2++0.3 Zn2+ 6.4±0.2* 10.4±0.9* 106.6±5.1* −32.4±2.4 9.5±0.5* −12.2±2.4 7.3±0.5 16
2 Ca2++2 Zn2+ 9.6±0.4* 16.6±3.2* 110.5±16.0* −29.1±3.1 12.2±2.5* −5.6±2.1* 7.8±0.6 16
0.3 Ca2++2 Zn2+ 14.7±0.5* 116.3±10.6a −21.8±2.6* 11.4±1.8* 6.9±2.4* 8.3±1.2* 16
2 Zn2+ (0 Ca2+) 15.2±0.4* 120.3±10.7a −20.2±2.3* 10.6±0.5* 7.5±1.8* 8.7±1.3* 20
Mean values (±SEM) were obtained at 0 mV from an HP of −80 mV
*p<0.05, with respect to 2-mM Ca2+ (0 mM Zn2+ )
a The inactivation time course could only be fitted to a single exponential
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the presence of various cations. Zn2+, both external and
internal, was reported earlier to slow the activation kinetics
of Na+ and K+ [21, 43]. In agreement with previous works
[6, 17, 32], we demonstrate that, in the absence of Ca2+, IZn
occurs with much lower amplitude and slower kinetics than
ICaL. Our observations are in full agreement with the initial
paper by Kawa [30], which reported the occurrence of Zn2+-
dependent cardiac action potential and inferred that Zn2+
ions are 5–10 times stronger in affinity to Ca2+ channels
than Ca2+ ions but 10–20 times less permeant. The much
higher affinity of the channel to Zn2+ might account for the
lower efficacy of nifedipine to inhibit the current. As already
reported for the HVA-Ca2+ currents in neurons [32], IZn is
increased by acidic pH; however, in our experimental con-
ditions, the cardiac L-type current demonstrates no signifi-
cant change in its reversal potential. In the presence of
2 mM Ca2+, Zn2+ reduces the cationic current in a
concentration-dependent manner but some current still
occurs at high Zn2+ concentration. However, adding
0.3 mM Ca2+ to the 2-mM Zn2+-containing solution did
not significantly affect the current, suggesting that Zn2+
permeation and blockade of current through the Ca2+ chan-
nel may occur simultaneously as proposed earlier for the
interactions of Zn2+ and Mg2+ with the N-methyl-D-aspartic
acid (NMDA) receptor-gated channel [5]. Like for the Na+
and K+ currents [20, 21], Zn2+ substantially slowed Ca2+
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current activation without having much effect on its deactiva-
tion. This was attributed to the presence of two independent
binding sites for Zn2+, one responsible for current reduction
and the other for gating shift [59]. In our case, Zn2+ effects on
L-type current properties could be related to a similar mech-
anism. The observed variations in current time-to-peak, V0.5,
and s correspondwell to alterations in the gating process of the
L-type Ca2+ channel. However, we obtained no strong evi-
dence for a surface charge screening effect of Zn2+ on the L-
type Ca2+ channel. Replacing external Ca2+ by Zn2+ (constant
divalent concentration of 2 mM), besides the effects on current
kinetics, shifted rightward the threshold and the activation
curve of the cationic current by ∼20 mV, which is much more
than that expected from a surface charge effect at this low
divalent concentration. As shown in Table 1 and Fig. 2b, a
similar shift in activation (and threshold) by 2 mM Zn2+ was
also seen when Ca2+ was decreased to 0.3 mM.
Zn2+ intracellularly applied also modulates ionic cur-
rents. It facilitates the downward regulation of a background
Cl− conductance [44] and inhibits cardiac ICaL [52]. In our
work, the intracellular Zn2+-induced inhibitory effect on
ICaL appears to be quite efficient, with an IC50 of ∼13 nM,
similar to the one of the external high-affinity site also
shown to reduce ICaL. Several mechanisms can be suggested
to account for these inhibitory effects. They include binding
on specific sites controlling cation permeation. Such potent
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inhibitions were reported for the acid-sensing ion channel
and the NMDA current by extracellular Zn2+ that were both
attributed to Zn2+ binding to a lysine [14, 39]. Moreover, it
was suggested that Zn2+ and H+ inhibition might share
common structural determinants, including a lysine [48]. It
was later shown that extracellular Zn2+ could enhance H+
sensitivity because the shift in IC50 for H
+ inhibition corre-
lates strongly with the percentage of Zn2+ inhibition caused
by various concentrations of Zn2+ [13]. In a more recent
work, it is shown that a mutation of His128 eliminates
nanomolar Zn2+ affinity of the NMDA receptors, whereas
other receptor properties including H+ inhibition are unaf-
fected [16]. Another described mechanism to account for
ICaL decrease could involve PKC activation, as shown in
retinal ganglion cell somata where intracellular Zn2+ facili-
tates the downward regulation of a background Cl− current
by an endogenous PKC [44]. PKC activation inhibits
cardiac ICaL, although conflicting findings have also been
observed in studies with direct activators of PKC, as distinct
isoforms of PKC may have opposing effects on L-type Ca2+
channels [29, 31]. However, the marked changes in kinetics
observed in our study have never been reported with PKC
activation, which makes this pathway less likely probable. A
more complex pathway that might involve the redox system
is discussed below.
A noticeable observation along this work was the strong
reduction of the β-adrenergic stimulation of ICaL by both
external and internal Zn2+. ISO stimulation of IZn is very
weak, one fourth of the one observed with ICaL, probably as
a consequence of Zn2+ entry. Furthermore, intracellular Zn2+,
besides reducing ICaL, antagonizes the β-adrenergic stimula-
tion of ICaL 16-fold more efficiently with an IC50 below 1 nM.
Increased Zn2+ uptake during long-term potentiation (LTP)
has also been reported to inhibit AC in hippocampal mossy
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fibers and so to account for the mechanism of zinc-mediated
attenuation of mossy fiber LTP [3]. In vitro, Zn2+ inhibition of
cAMP signaling has been attributed both to an inhibition of
AC, particularly the AC5 and AC6 isoforms [33] that are
present in the cardiomyocytes [40] and of the Gαs function
[19]. Of note, the prestimulated enzyme is less susceptible to
Zn2+ inhibition [33], accounting for the observation that ISO-
stimulated IZn is much larger (over twofold) when the β-
adrenergic stimulation has been first applied on ICaL in the
absence of Zn2+. The effect of FSK, strongly inhibited
by Zn2+, also suggests a major interaction of Zn2+ with AC. In
our work, the involvement of such a direct inhibition of AC by
Zn2+ is supported by the fact that cAMP added to the pipette
solution increases ICaL independently of the presence of up to
30 nM added Zn2+, potentially excluding Zn2+ effects at a later
stage of the stimulating cascade.
Zn2+ is often used as an antioxidant but it can also lead to
the release of reactive oxidative species [37] while the
oxidant induces the release of Zn2+ [53]. In our work, as
previously reported [26], the acute application of H2O2 had
little if any effect on ICaL, while it slightly reduces IZn but
fully inhibits the ISO effect on both ICaL and IZn. It is also
reported that long-term H2O2 upregulates ICaL but reduces
the sensitivity of the channel to β-adrenergic stimulation
[56]. One might consider that, on applying H2O2, the pri-
mary inhibition of the ISO effect results from H2O2-induced
Zn2+ release and consequent Zn2+ inhibition of AC that has
a much higher affinity to Zn2+ inhibition than ICaL. Further-
more, in our work, the effects of Zn2+ through changes in
ROS on ICaL and on its β-adrenergic stimulation are very
limited since the application of DTT did not modify IZn, theT
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Zn2+-induced inhibition of ICaL, or the effects of ISO on
these currents. In a recent work, it was reported that the β-
adrenergic effect on ICaL is mediated by an increased mito-
chondrial ROS production on the basis that the general
antioxidant NAC reduces the ISO effect [2]. However, ox-
idative stress may alter cardiac function by affecting [Zn2+]i,
most probably by inducing Zn2+ release from various cat-
ionic binding sites [50, 52]. Nevertheless, NAC displays
heavy metal-complexing potential with one Kd at 6.35 μM
[12]. It should thus be considered that, after the addition of
NAC, intracellular Zn2+ is clamped at a value much over the
nanomolar range that might well account for the reported
slight decrease in ICaL, for the marked reduction of the ISO
effect, as well as for the slight rightward shift of the I–V
curve (Fig. 6B in [2]) as we observed when adding 10-nM
Zn2+ to the pipette solution.
The β-adrenergic response is impaired under pathologi-
cal conditions such as diabetes [18, 45], leading to malad-
aptative elevation of circulating catecholamines. The
diminished inotropic responsiveness has been attributed to
a reduction in the number of β-adrenergic receptors, a defect
in their coupling to AC, as well as an altered sarcoplasmic
reticulum function without much change in the ICaL [45],
despite the abilities of ISO and FSK to stimulate AC in
membrane prepared from diabetic hearts [18]. Of note, by
altering the redox status, antioxidants such as selenium
restore depressed β1-adrenergic response in the diabetic
hearts [10]. Due to our observations, one can suggest that
the selenium-induced beneficial effect results from the
reported decrease in the intracellular Zn2+ [7].
The physiological consequences of our observations are
potentially quite important, considering that both extracel-
lular and intracellular Zn2+ concentrations are modulating,
respectively, Ca2+ influx and its β-adrenergic stimulation.
On the other hand, we show that external Zn2+, besides
being permeant, has an inhibitory effect on ICaL at con-
centrations as low as some tens of nanomolars. The plas-
ma Zn2+ content is reported to be 0.946 mg/L (∼14 μM)
[47]. Despite the fact that we do not know the precise free
Zn2+ concentration in the intercellular cardiac space, we
can anticipate a free Zn2+ level well over the nanomolars
contributing to a sustained inhibitory effect of Zn2+ on the
Ca2+ influx in situ. In diabetes, plasma Zn2+ content is
reduced [27, 48] which might favor Ca2+ influx and thus
contribute to Ca2+ overload. More clear and important is
the fact that the intracellular Zn2+ concentration is well
above the IC50 for the inhibition of β-adrenergic stimula-
tion such that any change in Zn2+ level will have a
significant effect on this hormonal modulation. Under
pathological conditions, such as diabetes and aldosteron-
ism, intracellular Zn2+ level is increased [7, 27, 28] ac-
counting, at least in part, for the reduced β-adrenergic
stimulation generally reported.
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